Colgate-Palmolive Company filings document a global consumer-products issuer with NYSE-listed common stock and registered debt securities. The company's 8-K reports cover earnings releases, the Strategic Growth and Productivity Program, reportable operating segment realignments, senior-note activity, debt-listing changes and governance events such as director elections and officer succession.
Proxy materials describe board elections, executive compensation, shareholder voting matters and strategic priorities tied to growth, efficiency and cash flow. The filings also identify registered securities, including common stock and multiple note series, and provide formal records for shareholder meetings, compensation arrangements and changes affecting listed note classes.
Colgate-Palmolive (NYSE: CL) filed an 8-K dated 1 Aug 2025 reporting two material items.
- Item 2.02 – Earnings release: The Q2-25 earnings press release was furnished as Exhibit 99; the filing itself contains no revenue, EPS or margin data and is not deemed “filed” for Exchange Act liability purposes.
- Item 2.05 – Three-year Productivity Program: Approved 31 Jul 2025, the initiative is intended to support the company’s 2030 strategy by streamlining the organisational structure and optimising the global supply chain. Management expects cumulative pre-tax charges of $200-$300 million, classified in the Corporate segment, with substantially all costs recognised by 31 Dec 2028.
The company cautions that forward-looking statements about timing and amount of charges may differ materially from current projections. No cost-savings targets, head-count impacts or earnings guidance were disclosed.
Colgate-Palmolive (NYSE: CL) submitted a routine Form 3 – Initial Statement of Beneficial Ownership for newly reported insider John Hazlin, Chief Growth Officer.
The filing shows Hazlin directly owns 14,385 common shares and indirectly owns 5,382 shares through the company’s 401(k) plan, for a total of 19,767 shares of common stock. In addition, he holds five separate stock-option grants covering an aggregate 103,340 underlying shares with exercise prices ranging from $72.83 to $106.34 and expiration dates between 2028 and 2032. Vesting schedules are disclosed for each grant, generally becoming exercisable in one-third increments starting one year after the grant date.
No purchases, sales or other transactions occurred on the reported event date (06/16/2025); the form simply establishes Hazlin’s beneficial ownership under Section 16(a). The filing contains no financial results, strategic updates, or other material corporate events.